长期偏向性β-抑制蛋白信号传导改善扩张型心肌病的心脏结构与功能
本研究在表达突变原肌球蛋白(Tm-E54K)的扩张型心肌病小鼠模型中,分别使用β-抑制蛋白2偏向性血管紧张素II受体配体TRV120067或血管紧张素II受体阻滞剂氯沙坦治疗3个月。结果显示TRV120067治疗组心脏结构与功能改善,而氯沙坦组无改善;TRV120067组肌丝钙反应性显著改善,与MLC2v和MYPT1/2磷酸化增加相关,由β-抑制蛋白介导的ERK1/2-RSK3信号激活所致。作者认为长期β-抑制蛋白2偏向性激动可能是扩张型心肌病的可行治疗途径。
要点
- TRV120067治疗的Tm-E54K小鼠心脏结构与功能改善,氯沙坦治疗组无改善。
- TRV120067组肌丝钙反应性显著改善,未治疗Tm-E54K小鼠该反应性降低。
- 功能改善与MLC2v和MYPT1/2磷酸化增加相关,由β-抑制蛋白介导的ERK1/2-RSK3信号激活所致。
核心结论
- 长期β-抑制蛋白2偏向性血管紧张素II受体激动可能通过防止适应不良信号并经由β-抑制蛋白信号通路改变肌丝钙反应性来改善心脏功能,从而成为扩张型心肌病的可行治疗途径。
研究设计与样本
- 研究为动物实验,使用表达突变原肌球蛋白(Tm-E54K)的扩张型心肌病小鼠模型。
- 小鼠分别接受TRV120067(β-抑制蛋白2偏向性血管紧张素II受体配体)或氯沙坦(血管紧张素II受体阻滞剂)治疗3个月。
- 治疗结束后评估心脏超声、去垢剂提取纤维束的肌丝钙反应性,并采用蛋白质组学方法分析翻译后修饰变化。
- 还评估了体内及分离心肌细胞中改变的信号通路。
主要发现
- TRV120067治疗的Tm-E54K小鼠心脏结构与功能改善,而氯沙坦治疗组无改善。
- TRV120067治疗的Tm-E54K小鼠肌丝钙反应性显著改善,未治疗Tm-E54K小鼠该反应性降低。
- MLC2v和MYPT1/2磷酸化增加仅见于TRV120067治疗组。
- 功能变化归因于β-抑制蛋白介导的ERK1/2-RSK3信号激活,可能通过β-抑制蛋白与肌节局部相互作用增加MLC2v磷酸化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biased agonism of the angiotensin II receptor is known to promote cardiac contractility. Our laboratory indicated that these effects may be attributable to changes at the level of the myofilaments. However, these signaling mechanisms remain unknown. Because a common finding in dilated cardiomyopathy is a reduction in the myofilament-Ca2+ response, we hypothesized that β-arrestin signaling would increase myofilament-Ca2+ responsiveness in a model of familial dilated cardiomyopathy and improve cardiac function and morphology. METHODS: We treated a dilated cardiomyopathy-linked mouse model expressing a mutant tropomyosin (Tm-E54K) for 3 months with either TRV120067, a β-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II receptor blocker. At the end of the treatment protocol, we assessed cardiac function using echocardiography, the myofilament-Ca2+ response of detergent-extracted fiber bundles, and used proteomic approaches to understand changes in posttranslational modifications of proteins that may explain functional changes. We also assessed signaling pathways altered in vivo and by using isolated myocytes. RESULTS: TRV120067- treated Tm-E54K mice showed improved cardiac structure and function, whereas losartan-treated mice had no improvement. Myofilaments of TRV120067-treated Tm-E54K mice had significantly improved myofilament-Ca2+ responsiveness, which was depressed in untreated Tm-E54K mice. We attributed these changes to increased MLC2v and MYPT1/2 phosphorylation seen only in TRV120067-treated mice. We found that the functional changes were attributable to an activation of ERK1/2-RSK3 signaling, mediated through β-arrestin, which may have a novel role in increasing MLC2v phosphorylation through a previously unrecognized interaction of β-arrestin localized to the sarcomere. CONCLUSIONS: Long-term β-arrestin 2-biased agonism of the angiotensin II receptor may be a viable approach to the treatment of dilated cardiomyopathy by not only preventing maladaptive signaling, but also improving cardiac function by altering the myofilament-Ca2+ response via β-arrestin signaling pathways.
引用
- Ryba DM, Li J, Cowan CL, et al. Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy. Circulation. 2017. PMID: 28104714. doi:10.1161/CIRCULATIONAHA.116.024482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。